Skip to content

Study to Investigate Sleep Apnea Patients at Altitude

Study to Investigate Sleep Apnea Patients at Altitude

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00514826
Enrollment
40
Registered
2007-08-10
Start date
2007-08-31
Completion date
2007-10-31
Last updated
2010-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea Syndrome

Brief summary

The purpose of the study is to investigate the effect of an altitude sojourn on patients with the obstructive sleep apnea syndrome

Detailed description

Previous observations do not allow to draw firm conclusions on the effect of altitude sojourn on sleep, breathing and daytime performance in patients with the obstructive sleep apnea syndrome. Furthermore, the susceptibility of sleep apnea patients to high altitude related illness is not known. Therefore, the purpose is to study untreated patients with obstructive sleep apnea syndrome living at low altitude during a sojourn of a few days at moderate altitude in order to evaluate the physiologic effects of hypobaric hypoxia in these patients. We hypothesize that: 1. Sleep and nocturnal breathing disturbances in untreated OSA patients are more pronounced at moderate altitude compared to low altitude. 2. The increase in sleep related breathing disturbances at moderate altitude is due to an increase in central apnea/hypopnea

Interventions

sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Obstructive sleep apnea syndrome based on symptoms and a sleep study

Exclusion criteria

* Sleep disorders other than obstructive sleep apnea syndrome * Other than mild, stable cardiovascular disease * Other than mild lung disease * Chronic rhinitis, previous uvulopalatopharyngoplasty * Treatment with drugs that affect respiratory center drive * Internal, neurologic or psychiatric disease that interferes with sleep quality * Previous intolerance to moderate or low altitude \< 2600m

Design outcomes

Primary

MeasureTime frame
Prevalence and severity of sleep disordered breathingduring altitude sojourn

Secondary

MeasureTime frame
alterations in sleep structure and vigilance; high altitude related illnessduring altitude sojourn

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026